Resistance to Herceptin (trastuzumab) in HER2 positive breast cancers: the role of calcium signalling.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1079672

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The monoclonal antibody therapy trastuzumab has revolutionized the treatment of women with Her2 positive breast cancer. Unfortunately some Her2 positive breast cancers do not respond to this therapy or gradually develop resistance. This project will define how an important cellular signal is remodeled in breast cancers resistant to trastuzumab. The ability of modulators of this signaling pathway to alter the sensitivity of breast cancers to trastuzumab will also be determined.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $620,292.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Pharmacology and Pharmaceutical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

breast cancer | calcium signalling | drug discovery | molecular pharmacology | pharmacology

Related Links